Skip To Main Content
Masuda Sharifi on Muck Rack

Masuda Sharifi

As seen in: MDPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Masuda

Contact Masuda, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer

|
By Amy Leslie, Zachary A. Schaaf, Shu Ning, Masuda Sharifi
| MDPI
1. Introduction Prostate cancer (PCa) is one of the most common types of cancer among men, with an estimated 1.4 million cases diagnosed annually worldwide [1]. Initial therapies utilized for treatment that work to reduce systemic androgens such as surgical castration/resection or anti-androgen therapeutics prove to be effective, however, in as little as just 5 years almost 20% of patients experience Castration-Resistant Prostate Cancer (CRPC) [2,3,4].
Open in Who Shared Issue with article?
See all 1 articles